Lista de obras - Norbert Grzasko - Dominio Público Uruguay

1q21 amplification with additional genetic abnormalities but not isolated 1q21 gain is a negative prognostic factor in newly diagnosed patients with multiple myeloma treated with thalidomide-based regimens

artículo científico publicado en 2012

A clinical comparison of the efficacy and safety of biosimilar G-CSF and originator G-CSF in haematopoietic stem cell mobilization.

artículo científico publicado en 2014

A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma

scientific article published on 18 February 2020

Acute T cell lymphoblastic leukemia in the recipient of a renal transplant from a donor with malignant lymphoma

artículo científico publicado en 2008

Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients.

artículo científico publicado en 2012

All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

scientific article published on 22 November 2018

Case-adjusted bortezomib-based strategy in routine therapy of relapsed/refractory multiple myeloma shown to be highly effective--a report by Polish Myeloma Study Group.

artículo científico publicado en 2014

Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.

artículo científico publicado en 2016

Cereblon (CRBN) gene polymorphisms predict clinical response and progression-free survival in relapsed/refractory multiple myeloma patients treated with lenalidomide: a pharmacogenetic study from the IMMEnSE consortium

scientific article published on 20 November 2019

Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group.

artículo científico publicado en 2017

Common gene variants within 3'-untranslated regions as modulators of multiple myeloma risk and survival

scientific article published on 05 November 2020

Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy

artículo científico publicado en 2016

Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients

scientific article published on 19 April 2020

Differential Function of a Novel Population of the CD19+CD24hiCD38hi Bregs in Psoriasis and Multiple Myeloma

artículo científico publicado en 2021

Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma.

artículo científico publicado en 2019

Expression and Clinical Significance of Neuropilin-1 in Patients With Multiple Myeloma

artículo científico publicado en 2020

Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients

artículo científico publicado en 2021

F-fluoro-ethyl-tyrosine (F-FET) PET/CT as a potential new diagnostic tool in multiple myeloma: a preliminary study

artículo científico publicado en 2019

Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study

article

High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell transplantation: A report of the Polish Myeloma Study Group.

artículo científico publicado en 2019

Identification of miRSNPs associated with the risk of multiple myeloma.

artículo científico publicado en 2016

Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1.

artículo científico publicado en 2017

Involvement of apoptosis and proinflammatory cytokines in the pathogenesis of anemia in multiple myeloma

artículo científico publicado en 2004

Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies

scientific article published on 08 May 2019

Long-term thalidomide therapy resulted in lack of mdr1 gene expression in a patient with primary resistant multiple myeloma.

artículo científico publicado en 2005

Lovastatin and thalidomide have a combined effect on the rate of multiple myeloma cell apoptosis in short term cell cultures.

artículo científico publicado en 2006

Optimizing the treatment of patients with multiple myeloma and renal impairment

artículo científico

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

artículo científico publicado en 2016

Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma

artículo científico publicado en 2018

Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma.

artículo científico publicado en 2016

Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients.

artículo científico publicado en 2018

Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients

artículo científico publicado en 2018

Stimulation of erythropoiesis by thalidomide in multiple myeloma patients: its influence on FasL, TRAIL and their receptors on erythroblasts.

artículo científico publicado en 2006

Thalidomide can promote erythropoiesis by induction of STAT5 and repression of external pathway of apoptosis resulting in increased expression of GATA-1 transcription factor

artículo científico publicado en 2015

Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma.

artículo científico publicado en 2011

The efficacy and safety of pomalidomide in relapsed/refractory multiple myeloma in a “real-world” study: Polish Myeloma Group experience

artículo científico publicado en 2018

The efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide, thalidomide, dexamethasone) regimen in patients with multiple myeloma--a report by the Polish Myeloma Study Group.

artículo científico publicado en 2010

Therapy-related peripheral neuropathy in multiple myeloma patients.

artículo científico publicado en 2014

[Evaluation of blood morphology in patients with refractory multiple myeloma treated with thalidomide]

scientific article published on 01 July 2001

[Hemostatic and fibrinolysis markers in the early phase of acute ischaemic stroke]

artículo científico publicado en 2004

Lista de obras de Norbert Grzasko

1q21 amplification with additional genetic abnormalities but not isolated 1q21 gain is a negative prognostic factor in newly diagnosed patients with multiple myeloma treated with thalidomide-based regimens

A clinical comparison of the efficacy and safety of biosimilar G-CSF and originator G-CSF in haematopoietic stem cell mobilization.

A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma

Acute T cell lymphoblastic leukemia in the recipient of a renal transplant from a donor with malignant lymphoma

Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients.

All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

Case-adjusted bortezomib-based strategy in routine therapy of relapsed/refractory multiple myeloma shown to be highly effective--a report by Polish Myeloma Study Group.

Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.

Cereblon (CRBN) gene polymorphisms predict clinical response and progression-free survival in relapsed/refractory multiple myeloma patients treated with lenalidomide: a pharmacogenetic study from the IMMEnSE consortium

Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group.

Common gene variants within 3'-untranslated regions as modulators of multiple myeloma risk and survival

Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy

Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients

Differential Function of a Novel Population of the CD19+CD24hiCD38hi Bregs in Psoriasis and Multiple Myeloma

Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma.

Expression and Clinical Significance of Neuropilin-1 in Patients With Multiple Myeloma

Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients

F-fluoro-ethyl-tyrosine (F-FET) PET/CT as a potential new diagnostic tool in multiple myeloma: a preliminary study

Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study

High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell transplantation: A report of the Polish Myeloma Study Group.

Identification of miRSNPs associated with the risk of multiple myeloma.

Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1.

Involvement of apoptosis and proinflammatory cytokines in the pathogenesis of anemia in multiple myeloma

Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies

Long-term thalidomide therapy resulted in lack of mdr1 gene expression in a patient with primary resistant multiple myeloma.

Lovastatin and thalidomide have a combined effect on the rate of multiple myeloma cell apoptosis in short term cell cultures.

Optimizing the treatment of patients with multiple myeloma and renal impairment

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma

Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma.

Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients.

Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients

Stimulation of erythropoiesis by thalidomide in multiple myeloma patients: its influence on FasL, TRAIL and their receptors on erythroblasts.

Thalidomide can promote erythropoiesis by induction of STAT5 and repression of external pathway of apoptosis resulting in increased expression of GATA-1 transcription factor

Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma.

The efficacy and safety of pomalidomide in relapsed/refractory multiple myeloma in a “real-world” study: Polish Myeloma Group experience

The efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide, thalidomide, dexamethasone) regimen in patients with multiple myeloma--a report by the Polish Myeloma Study Group.

Therapy-related peripheral neuropathy in multiple myeloma patients.

[Evaluation of blood morphology in patients with refractory multiple myeloma treated with thalidomide]

[Hemostatic and fibrinolysis markers in the early phase of acute ischaemic stroke]